Varaico: Literature-Extracted Genetic Variants

Gene:FMO3
Variant:p.M66I
Back to variants list

FMO3

NM_001002294.3:p.M66I

Associated Papers

APF2: an improved ensemble method for pharmacogenomic variant effect prediction.

Zhou Y et al.

The Pharmacogenomics Journal, 2024

38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1

Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.

Zhang T et al.

Peerj, 2024

39465171 (PubMed )
Supplement: peerj-12-18360-s002.7z › drug-metabolizing_enzymes_and_transporter__DMET__microarray › markerlist.xlsx › markerlist.TXT

Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources.

Makiguchi M et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023

Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.

Kim B et al.

Translational and Clinical Pharmacology, 2021

34621706 (PubMed )
Supplement: tcp-29-135-s001.xls › tcp-29-135-s001

An optimized prediction framework to assess the functional impact of pharmacogenetic variants.

Zhou Y et al.

The Pharmacogenomics Journal, 2019

30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1

GESPA: classifying nsSNPs to predict disease association.

Khurana JK et al.

Bmc Bioinformatics, 2015

26206375 (PubMed )
Supplement: 12859_2015_673_MOESM2_ESM.xls › Sheet1

Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.

Yamazaki H et al.

Biochemical Pharmacology, 2013

Flavin-containing monooxygenase 3 and human disease.

Motika MS et al.

Expert Opinion on Drug Metabolism & Toxicology, 2007

Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.

Yeung CK et al.

Archives of Biochemistry and Biophysics, 2007

Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.

Hisamuddin IM et al.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005

Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Krueger SK et al.

Pharmacology & Therapeutics, 2005

Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.

Hisamuddin IM et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004

The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.

Cashman JR

Drug Discovery Today, 2004

Trimethylaminuria and a human FMO3 mutation database.

Hernandez D et al.

Human Mutation, 2003

Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria.

Zhang J et al.

Pharmacogenetics, 2003

Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.

Cashman JR et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002

A novel deletion in the flavin-containing monooxygenase gene (FMO3) in a Greek patient with trimethylaminuria.

Forrest SM et al.

Pharmacogenetics, 2001

Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.

Störmer E et al.

British Journal of Clinical Pharmacology, 2000

Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome.

Dolphin CT et al.

Pharmacogenetics, 2000

A novel mutation in the flavin-containing monooxygenase 3 gene, FM03, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy.

Murphy HC et al.

Pharmacogenetics, 2000

Population-specific polymorphisms of the human FMO3 gene: significance for detoxication.

Cashman JR et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2000

Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism.

Sachse C et al.

Clinical Pharmacology and Therapeutics, 1999

Two novel mutations of the FMO3 gene in a proband with trimethylaminuria.

Akerman BR et al.

Human Mutation, 1999

Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication.

Treacy EP et al.

Human Molecular Genetics, 1998

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."